False Claims Act Insights - The Mathematics of Nuclear FCA Verdicts
Episode 379 -- Update on False Claims Act and Customs Evasion Liability
Episode 378 -- Update on Export Controls and Sanctions Enforcement
False Claims Act Insights - Bitter Pills: DOJ Targets Pharmacies for FCA Enforcement
From Permits to Penalties: A Deep Dive Into Coastal Development Law
10 For 10: Top Compliance Stories For the Week Ending June 21, 2025
Daily Compliance News: June 16, 2025, The Golden Share Edition
PODCAST: Williams Mullen's Benefits Companion - Forfeitures Under Fire
GILTI Conscience Podcast | Navigating Brazil's New Transfer Pricing Landscape: A Shift to OECD Standards
Episode 371 -- DOJ's New Corporate Enforcement Program
REFRESH Nonprofit Basics: Federal Tax Filing Deadlines and Penalties
Episode 369 -- Stepping Into the Enforcement Spotlight -- Customs and Border Patrol and Import Enforcement
Insider Transaction Traps for the Unwary
Nonprofit Basics: Federal Tax Filing Deadlines and Penalties
JONES DAY PRESENTS®: Harmonizing Global Protections: The EU Trade Secret Directive
JONES DAY PRESENTS®: Taiwan's Enhanced Trade Secret Restrictions and Stricter Penalties
Economic Substance: Practical Advice 3 Years On …
Wait, that’s covered? Insurability of Fines and Penalties Flowing From a Cybersecurity Breach
#WorkforceWednesday: OSHA Issues COVID-19 Citations, Michigan Enacts Liability Shield, and States Battle for Telecommuter Taxes - Employment Law This Week®
False Claims Act Implications for PPP and Disaster Relief Loans: What Small Businesses Should Be Ready For
The False Claims Act continues to be one of the most commonly used weapons in the government’s enforcement arsenal to address various forms of fraud. In addition to our “Year in Review” publication providing an overview of...more
On 4 July 2025, the EC fined Alchem and its subsidiary EUR 489,000 for their role in a long-running cartel concerning the active pharmaceutical ingredient SNBB, used in the production of Buscopan and its generics. This marks...more
On May 9, 2025, the Tianjin Municipal Administration for Market Regulation (“Tianjin AMR”) announced administrative penalties against four manufacturers of dexamethasone sodium phosphate (“DSP”) active pharmaceutical...more
Medical device manufacturers and distributors have come under increasing scrutiny from state licensing agencies and operating without a required license may lead to severe consequences. These can include financial penalties;...more
CFIUS reviewed a record number of transactions in 2021 according to its most recent annual report – and shows no signs of slowing down. High technology (including quantum computing), life sciences, and green energy...more